At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Use of Sanofi’s dengue vaccine, the world’s first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection.

Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.

New data from Novartis’ breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid efforts to muscle in on turf dominated by rival Pfizer’s Ibrance.

Ignyta updated results from its STARTRK-2 clinical trial of entrectinib in non-small cell lung cancer (NSCLC), causing company stock to jump about five percent before settling down.

Acerta Pharmaceuticals is being forced to retract claims of a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer that was published in three medical journals two years ago due to falsified data.

Shares of Zogenix Inc. more than doubled following the company’s announcement that its investigational Dravet syndrome drug met its primary endpoints in cutting seizure rates in juvenile patients.

Giving Merck & Co.’s immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial.

After a big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation in September 2017 when it unveils full details of two key clinical trials tackling the disease in different ways.

Specialty pharmaceutical company Mallinckrodt plc struck a deal to acquire privately held InfaCare, a Pennsylvania-based company focused on therapies for neonatal and pediatric patients.